Last Updated: January 23, 2023

   
     


 
Featured Articles

A Treatment Timeline

POZ Magazine | January 17, 2023

Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV 

Gilead | December 22, 2022

FDA Approves SUNENCA (lenacapavir) for Adults with Limited Treatment Options

FDA | December 22, 2022

Blue Cross and Blue Shield Accused of Placing Most HIV Drugs into Highest Tiers

POZ | December 8, 2022

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society–USA Panel

JAMA. 2022; doi:10.1001/jama.2022.22246. [epublished online December 1, 2022]

Exciting alternatives: An overview of long-acting HIV treatment, prevention

Healio | October 2022

American Academy of HIV Medicine Launches Long-Acting Agent Resource Center

American Academy of HIV Medicine | August 22, 2022

Long-acting Agent Resource Center website

HIV LAA | August 2022

2022 HIV Drug Chart

POZ | June 27, 2022

12 Surprisingly Interesting Facts About Making Medicines And The Pharma Industry

Sintered Filter | May 10, 2022

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

HIV.gov | January 20, 2022

Updates in the Pipeline of HIV Therapy

Infectious Disease Special Edition | January 14, 2022

   
News Updates

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial 

Lancet HIV. 2023 Jan;10(1):e15-e23. doi: 10.1016/S2352-3018(22)00291-0.

FDA approves Sunlenca for treatment-resistant HIV

Medical Xpress | December 29, 2022

Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak 

Am J Ophthalmol Case Rep. 2022 Dec 13;101779. doi: 10.1016/j.ajoc.2022.101779.

High-Resistance Therapy Options for Treatment-Naïve Patients With HIV

ContagionLive | December 9, 2022

Antiretroviral Drugs for HIV Clinical Practice Guidelines (IAS,2022)

Medscape | December 9, 2022

Do Antidepressants Make HIV Meds Less Effective?

Plus Magazine | December 9, 2022

First clinical trial of possible HIV vaccine shows promising results

kpbs.org | December 8, 2022

Toolkit: Long-Acting Injectables in HIV Treatment

TargetHIV | November 15, 2022

Fostemsavir Plus Optimized Background Therapy May Be Viable for MDR HIV

Dolutegravir Effectively Suppresses HIV in Pregnant Women

Contagion Live | November 2, 2022

FDA reports shortages of amoxicillin (November 1, 2022)

The Hill | November 1, 2022

HepB-CpG Vaccination Achieves Maximum Seroprotection in Patients With HIV 

Infectious Disease Advisor | October 28, 2022

Tybost (Cobicistat) - Oral: Uses, Side Effects, Dosages, Interactions

Verywell Health | October 28, 2022

European Medicines Agency Validates Viiv Healthcare's Marketing Authorisation Application For Cabotegravir Long-Acting Injectable For HIV Prevention

ViiV Healthcare | October 28, 2022

Gilead's latest Biktarvy data offers hope to HIV patients

PMLiVE | October 25, 2022

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection 

Retrovirology. 2022 Oct 22;19(1):22. doi: 10.1186/s12977-022-00608-1.

Tolerability Drives Most ART Switch Decisions in Patients Living With HIV/AIDS 

Contagion Live | October 21, 2022

Long-Term Biktarvy Resulted in High Rates of Viral Suppression 

Infectious Disease Special Edition | October 20, 2022

   

 
           
  2019 Archives 2020 Archives 2021 Archives 2022 Archives